Product logins

Find logins to all Clarivate products below.


Last Updated 22 October 2015
The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal agents Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Medivation/Astellas Pharma’s enzalutamide) compete fiercely in this setting. The prostate cancer drug development pipeline is dynamic, and agents in late-phase development span a wide range of drug classes. The expected launch of several emerging therapies for prostate cancer over 2014-2024 will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.

Related Market Assessment Reports

Report
Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer | Disease Landscape & Forecast | G7 | 2025
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Report
Prostate Cancer – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Report
Prostate Cancer – Unmet Need – Unmet Need – Metastatic Hormone-Sensitive Prostate Cancer (US/EU)
Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…